Korro Bio Reports Q3 GAAP EPS of -$0.98, Exceeding Analyst Expectations
Korro Bio (KRRO) reported third-quarter earnings with a GAAP EPS of -$0.98, which outperformed market expectations by $0.38. Despite the beat, the company noted that it generated no collaboration revenue during this period. As of September 30, 2026, Korro Bio maintained a strong liquidity position, reporting $124.8 million in cash, cash equivalents, and marketable securities. The results highlight the company's ongoing operational phase as it manages its capital reserves.
Tickers: $KRRO
Topics: cash position earnings beat GAAP EPS